Church & Dwight (CHD)
Consumer Staples · $22.9B market cap · SEC CIK 0000313927
$96.12
▲+0.66% on the day
close of Sep 22, 2026
58
Screens well
fundamentals score out of 100
fundamentals score out of 100
Next reports on Oct 29, 2026, before the open, with analysts expecting $0.91 in earnings per share.
The case for CHD
- Generated $1.1B of free cash flow in FY2025, 18% of revenue.
- Earnings per share up 46.6%.
- A PEG of 0.66: a P/E of 30.7× is low for EPS growing 47%.
- Return on equity of 18%.
- Moves less than the market (beta 0.47).
- Pays a modest 1.1% dividend.
The case against
- Pricey at 30.7× earnings, against a long-run market average nearer 20×.
- Long-term debt of $2.2B against $409M of cash.
- Price/sales of 3.7× is higher than 86% of Consumer Staples companies.
- Revenue grew only 2.7%, roughly the pace of inflation.
What the score is made of
Each factor is half a curve over reported figures and half a rank among the other Consumer Staples companies (momentum is judged against fixed thresholds only), and the five are blended by weight. It describes the last filing and the current price. It is not a forecast.
| Valuewhat you pay for the earnings, sales, assets and cash | 38 |
|---|---|
| Growthhow fast revenue and earnings are moving, this year and over five | 63 |
| Profitabilityhow much of the revenue becomes profit, and how much of that is cash | 65 |
| Momentumhow the price has behaved lately | 55 |
| Stabilityhow violently it moves, what it owes and what it pays you | 75 |
- Each factor except momentum is half fixed thresholds, half rank among the 36 Consumer Staples companies.
Key numbers
| Price / earnings | 30.7× |
|---|---|
| Price / book | 5.28× |
| Price / sales | 3.7× |
| Revenue growth (YoY) | +2.7% |
| EPS growth (YoY) | +46.6% |
| Gross margin | 46% |
| Operating margin | 17% |
| Net margin | 12% |
| Return on equity | 18% |
| Debt / equity | 0.52× |
| Current ratio | 1.15 |
| Dividend yield | 1.15% |
| Beta | 0.47 |
| 52-week range | $81.33 – $106.04 |
| Position in that range | 60% of the way up |
| 3-month return | -0.1% |
| 1-year return | +5.7% |
Five years of financials, as filed
Pulled from Church & Dwight's XBRL filings on SEC EDGAR. Italic rows are derived from the rows above.
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | |
|---|---|---|---|---|---|
| Revenue | $6.2B | $6.1B | $5.9B | $5.4B | $5.2B |
| Gross profit | $2.8B | $2.8B | $2.6B | $2.3B | $2.3B |
| Operating income | $1.1B | $807M | $1.1B | $598M | $1.1B |
| Net income | $737M | $585M | $756M | $414M | $828M |
| Operating cash flow | $1.2B | $1.2B | $1.0B | $885M | $994M |
| Capital expenditure | $122M | $180M | $224M | $179M | $119M |
| Total assets | $8.9B | $8.9B | $8.6B | $8.3B | $8.0B |
| Total liabilities | $4.9B | $4.5B | $4.7B | $4.9B | $4.8B |
| Shareholder equity | $4.0B | $4.4B | $3.9B | $3.5B | $3.2B |
| Cash | $409M | $964M | $345M | $270M | $241M |
| Long-term debt | $2.2B | $2.2B | $2.2B | $2.6B | $2.2B |
| Free cash flow | $1.1B | $976M | $807M | $706M | $875M |
| Gross margin | 44.7% | 45.7% | 44.1% | 41.9% | 43.6% |
| Operating margin | 17.4% | 13.2% | 18.0% | 11.1% | 20.8% |
| Net margin | 11.9% | 9.6% | 12.9% | 7.7% | 15.9% |
| Diluted shares | 244M | 247M | 248M | 246M | 250M |
Share count is essentially flat over 4 years.
Risk factors CHD lists in its 10-K
- Medical Device Clearance and Approval
- OTC/Pharmaceutical and Cosmetic Requirements
- Medical Device, OTC/Pharmaceutical and Cosmetic Pre- and Post-Market Regulation
- We face intense competition in our markets
- A continued change in the retail environment and changing consumer preferences could cause our sales to decline
- Volatility and increases in the price of raw and packaging materials or energy costs could erode our profit margins
- Loss of any of our principal customers could significantly decrease our sales and profitability
- Market category declines and changes to our product and geographic mix may impact the achievement of our sales growth targets, planned pricing and financial results
- Decreases in demand for our products would decrease our sales and profitability
- We rely on the policies of our key retail customers
- We may be unable to successfully identify, finance, complete and integrate future strategic acquisitions, or successfully complete or realize the anticipated benefits of strategic divestitures
- New products and product line extensions may not gain widespread customer acceptance, may be otherwise discontinued, or cause sales of existing products to decline
- Reduced availability of transportation or disruptions in our transportation network could adversely affect us
- Damage to the reputation of one or more of our leading brands could adversely affect us